Cargando…
Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678915/ https://www.ncbi.nlm.nih.gov/pubmed/29404494 http://dx.doi.org/10.1002/hep4.1080 |
_version_ | 1783277536436813824 |
---|---|
author | Kamada, Yoshihiro Ono, Masafumi Hyogo, Hideyuki Fujii, Hideki Sumida, Yoshio Yamada, Makoto Mori, Kojiroh Tanaka, Saiyu Maekawa, Tomohiro Ebisutani, Yusuke Yamamoto, Akiko Takamatsu, Shinji Yoneda, Masashi Kawada, Norifumi Chayama, Kazuaki Saibara, Toshiji Takehara, Tetsuo Miyoshi, Eiji |
author_facet | Kamada, Yoshihiro Ono, Masafumi Hyogo, Hideyuki Fujii, Hideki Sumida, Yoshio Yamada, Makoto Mori, Kojiroh Tanaka, Saiyu Maekawa, Tomohiro Ebisutani, Yusuke Yamamoto, Akiko Takamatsu, Shinji Yoneda, Masashi Kawada, Norifumi Chayama, Kazuaki Saibara, Toshiji Takehara, Tetsuo Miyoshi, Eiji |
author_sort | Kamada, Yoshihiro |
collection | PubMed |
description | In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for effective NAFLD surveillance. Mac‐2 binding protein (Mac‐2bp) is a useful nonalcoholic steatohepatitis (NASH) diagnosis biomarker and a powerful prediction biomarker for NAFLD fibrosis stage. Wisteria floribunda agglutinin (WFA)‐positive Mac‐2bp (WFA(+)‐M2BP) is a novel serum fibrosis biomarker for chronic hepatitis C that has clinical validity. Mac‐2bp and WFA(+)‐M2BP are also clinical NAFLD biomarker candidates. We examined the efficacy of Mac‐2bp and WFA(+)‐M2BP for NAFLD assessment using patients with biopsy‐proven NAFLD (n = 510; NAFLD cohort) and subjects who received a health check‐up (n = 2,122; check‐up cohort). In the NAFLD cohort, we set the fibrosis predicting cutoff values as 1.80 (F1), 2.21 (F2), and 2.24 μg/mL (F3). In the subjects with fatty liver from the check‐up cohort (n = 1,291), the serum Mac‐2bp levels were >1.80 μg/mL in 38.6% of the subjects (n = 498), and >2.24 μg/mL in 24.6% of the subjects (n = 318). The NAFLD cohort results indicated that Mac‐2bp and WFA(+)‐M2BP were equally useful for NASH diagnosis. During the early stages of fibrosis (F1, F2), the increase in Mac‐2bp was statistically significant but WFA(+)‐M2BP did not increase. Logistic regression analysis revealed that Mac‐2bp was an independent determinant for the prediction of advanced fibrosis stage (≥F2), even when adjusted for WFA(+)‐M2BP. Immunohistochemical staining of Mac‐2bp revealed that hepatocytes strongly expressed Mac‐2bp in patients with NAFLD. Conclusion: Our results indicated that hepatocyte‐derived Mac‐2bp would be a useful single biomarker for NASH diagnosis and fibrosis stage prediction in patients with NAFLD. (Hepatology Communications 2017;1:780–791) |
format | Online Article Text |
id | pubmed-5678915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-56789152018-02-05 Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis Kamada, Yoshihiro Ono, Masafumi Hyogo, Hideyuki Fujii, Hideki Sumida, Yoshio Yamada, Makoto Mori, Kojiroh Tanaka, Saiyu Maekawa, Tomohiro Ebisutani, Yusuke Yamamoto, Akiko Takamatsu, Shinji Yoneda, Masashi Kawada, Norifumi Chayama, Kazuaki Saibara, Toshiji Takehara, Tetsuo Miyoshi, Eiji Hepatol Commun Original Articles In contrast to patients with viral hepatitis, patients with nonalcoholic fatty liver disease (NAFLD) can progress to hepatocellular carcinoma during the initial stages of liver fibrosis. Development and implementation of noninvasive methods for diagnosis and progression prediction are important for effective NAFLD surveillance. Mac‐2 binding protein (Mac‐2bp) is a useful nonalcoholic steatohepatitis (NASH) diagnosis biomarker and a powerful prediction biomarker for NAFLD fibrosis stage. Wisteria floribunda agglutinin (WFA)‐positive Mac‐2bp (WFA(+)‐M2BP) is a novel serum fibrosis biomarker for chronic hepatitis C that has clinical validity. Mac‐2bp and WFA(+)‐M2BP are also clinical NAFLD biomarker candidates. We examined the efficacy of Mac‐2bp and WFA(+)‐M2BP for NAFLD assessment using patients with biopsy‐proven NAFLD (n = 510; NAFLD cohort) and subjects who received a health check‐up (n = 2,122; check‐up cohort). In the NAFLD cohort, we set the fibrosis predicting cutoff values as 1.80 (F1), 2.21 (F2), and 2.24 μg/mL (F3). In the subjects with fatty liver from the check‐up cohort (n = 1,291), the serum Mac‐2bp levels were >1.80 μg/mL in 38.6% of the subjects (n = 498), and >2.24 μg/mL in 24.6% of the subjects (n = 318). The NAFLD cohort results indicated that Mac‐2bp and WFA(+)‐M2BP were equally useful for NASH diagnosis. During the early stages of fibrosis (F1, F2), the increase in Mac‐2bp was statistically significant but WFA(+)‐M2BP did not increase. Logistic regression analysis revealed that Mac‐2bp was an independent determinant for the prediction of advanced fibrosis stage (≥F2), even when adjusted for WFA(+)‐M2BP. Immunohistochemical staining of Mac‐2bp revealed that hepatocytes strongly expressed Mac‐2bp in patients with NAFLD. Conclusion: Our results indicated that hepatocyte‐derived Mac‐2bp would be a useful single biomarker for NASH diagnosis and fibrosis stage prediction in patients with NAFLD. (Hepatology Communications 2017;1:780–791) John Wiley and Sons Inc. 2017-08-16 /pmc/articles/PMC5678915/ /pubmed/29404494 http://dx.doi.org/10.1002/hep4.1080 Text en © 2017 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Kamada, Yoshihiro Ono, Masafumi Hyogo, Hideyuki Fujii, Hideki Sumida, Yoshio Yamada, Makoto Mori, Kojiroh Tanaka, Saiyu Maekawa, Tomohiro Ebisutani, Yusuke Yamamoto, Akiko Takamatsu, Shinji Yoneda, Masashi Kawada, Norifumi Chayama, Kazuaki Saibara, Toshiji Takehara, Tetsuo Miyoshi, Eiji Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
title | Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
title_full | Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
title_fullStr | Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
title_full_unstemmed | Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
title_short | Use of Mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
title_sort | use of mac‐2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678915/ https://www.ncbi.nlm.nih.gov/pubmed/29404494 http://dx.doi.org/10.1002/hep4.1080 |
work_keys_str_mv | AT kamadayoshihiro useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT onomasafumi useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT hyogohideyuki useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT fujiihideki useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT sumidayoshio useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT yamadamakoto useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT morikojiroh useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT tanakasaiyu useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT maekawatomohiro useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT ebisutaniyusuke useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT yamamotoakiko useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT takamatsushinji useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT yonedamasashi useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT kawadanorifumi useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT chayamakazuaki useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT saibaratoshiji useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT takeharatetsuo useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT miyoshieiji useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis AT useofmac2bindingproteinasabiomarkerfornonalcoholicfattyliverdiseasediagnosis |